Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference

Rhea-AI Summary

Nyxoah SA (Nasdaq: NYXH) announced its participation in the Baird 2021 Global Healthcare Conference, scheduled for September 14, 2021. CEO Olivier Taelman and CFO Fabian Suarez will present virtually at 3:05 pm CET / 9:05 am ET. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA), with its leading product, the Genio® system, receiving CE Mark approval in 2019 following successful clinical trials. The company is currently conducting the DREAM IDE pivotal study for FDA approval and a European study to confirm the Genio® system's long-term effectiveness.

Positive

• Participation in the prestigious Baird 2021 Global Healthcare Conference can increase visibility.
• Successful completion of studies leading to CE Mark approval enhances credibility.
• Ongoing pivotal studies for FDA approval may open new markets.

Negative

• None.

PRESS RELEASE

Nyxoah Announces Participation in the Baird 2021 Global Healthcare Conference

Mont-Saint-Guibert, Belgium – September 2, 2021, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, and Fabian Suarez, Chief Financial Officer, will participate at the Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021, with a virtual presentation at 3:05 pm CET / 9:05 am ET.

A live webcast and replay of this event will be available on the Company’s investors relations website at https://investors.nyxoah.com/

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company has completed the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion and is currently conducting the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 (0)10 22 24 55

Gilmartin Group 
Vivian Cervantes
IR@nyxoah.com

Attachment

• ENGLISH - NYXH Announces Baird HC 2021 Conf - FINAL

FAQ

When is Nyxoah's presentation at the Baird 2021 Global Healthcare Conference?

Nyxoah's presentation is scheduled for September 14, 2021, at 3:05 pm CET / 9:05 am ET.

What is the focus of Nyxoah as a company?

Nyxoah focuses on developing and commercializing solutions for Obstructive Sleep Apnea (OSA).

What is the Genio® system?

The Genio® system is a CE-validated hypoglossal neurostimulation therapy for treating Obstructive Sleep Apnea.

Has Nyxoah received any regulatory approval for its products?

Yes, Nyxoah received the European CE Mark for the Genio® system in 2019.

What studies is Nyxoah currently conducting?

Nyxoah is conducting the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe.